Good News | Alioth Wins the Title of "2025 Top 50 Start-ups with the most Investment Potential in Shanghai"

The "2025 Top 50 Start-ups with the most Investment Potential in Shanghai Selection" is jointly organized by various parties, including the Shanghai Municipal Commission of Economy and Informatization, the Shanghai Coordination Office for Promoting the Development of Small and Medium-sized Enterprises, the Shanghai Small and Medium-sized Enterprise Development Service Center (Shanghai Small and Medium-sized Enterprise Listing Promotion Center), the Shanghai International Private Equity Fund Association, the Shanghai Equity Investment Association, and the Shanghai Venture Capital Industry Association, under the guidance of the Shanghai Municipal Commission of Economy and Informatization. This year marks the tenth consecutive year of its holding. The listed enterprises will be included in the "Shanghai Key Cultivated Start-up Enterprise Database," gaining more opportunities to connect with financial capital and engage in further exchanges and cooperation with nearly a hundred member units behind the three equity investment associations in Shanghai.

Alioth focuses on the development and application of pharmaceutical process filtration products and technologies based on "filter membrane" new materials. It addresses pain points in the biopharmaceutical industry chain, accelerates the overcoming of the "bottleneck" technology issues in high-performance filter membrane materials by continuously breaking through core technological barriers, and has constructed a complete solution from membrane material research and development to process optimization, providing a solid guarantee for the supply chain security of the pharmaceutical industry and the safe production of drugs.

Leveraging its comprehensive research and development capabilities in filter membrane materials and industrial layout, the company's filtration product series have been successfully applied in the production processes of over 50 clinical phase III/commercialized drugs. More than 100 application cases cover pharmaceutical fields such as antibodies, vaccines, recombinant proteins, blood products, CGT (Cell and Gene Therapy), and small molecules, comprehensively ensuring the drug production safety of pharmaceutical enterprises.

Since its establishment, Alioth has received equity investments from multiple domestic leading private equity funds multiple times, with a cumulative financing amount of several hundred million yuan.

Winning the honor of "2025 Top 50 Start-ups with the most Investment Potential in Shanghai" is a dual recognition from the capital market of Alioth's innovative technological achievements and industrial leadership in the high-end membrane material field. In the future, Alioth will continue to uphold the spirit of innovation, continuously enhance its core competitiveness, and contribute its own strength to promoting the high-quality development of China's biopharmaceutical industry!